Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION)

Dr Michael Morris - Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, USA

15 Jul 2021

OncoAlert and ecancer weekly round up for July 1- July 10, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

13 Jul 2021

ZUMA-3: KTE-X19, an anti-CD19 chimeric antigen receptor T-cell therapy for R/R B-cell acute lymphoblastic leukaemia

Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA

12 Jul 2021

Study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic oesophageal cancer

Dr Zev Wainberg - University of California Los Angeles, California, USA

12 Jul 2021

CodeBreaK 100: Patient-reported outcomes evaluating sotorasib in KRAS p.G12C mNSCLC

Dr Alex Spira - Virginia Cancer Specialists Research Institute, Fairfax, USA

6 Jul 2021

ASCO 2021: Lung roundup

Dr Luis Raez - Memorial Healthcare System, FL, USA

5 Jul 2021

ASCO 2021: Precision and molecular reporting for prostate cancer

Prof Eleni Efstathiou - Houston Methodist Cancer Center, Houston, USA

29 Jun 2021

Neo-AEGIS: Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy

Prof John Reynolds - Trinity College Dublin, Dublin, Republic of Ireland

29 Jun 2021

COSMIC-311: Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer

Dr Marcia Brose - University of Pennsylvania, Philadelphia, USA

$COSMIC-311: Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer ( Dr Marcia Brose - University of Pennsylvania, Philadelphia, USA )$

29 Jun 2021

The clinical value of maintenance in multiple myeloma

Prof Wee Joo Chng - National University of Singapore, Singapore

25 Jun 2021

Once weekly selinexor, carfilzomib, and dexamethasone (XKD) in carfilzomib non-refractory multiple myeloma patients

Prof Cristina Gasparetto - Duke Cancer Institute, Durham, USA

$Once weekly selinexor, carfilzomib, and dexamethasone (XKD) in carfilzomib non-refractory multiple myeloma patients ( Prof Cristina Gasparetto - Duke Cancer Institute, Durham, USA )$

25 Jun 2021

Isatuximab, carfilzomib, lenalidomide and dexamethasone for high risk MM

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany

25 Jun 2021

Video

More from ecancer